Journal Article
. 2011 Mar; 377(9769):914-23.
doi: 10.1016/S0140-6736(11)60070-6.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Javier Cortes 1 Joyce O'Shaughnessy  David Loesch  Joanne L Blum  Linda T Vahdat  Katarina Petrakova  Philippe Chollet  Alexey Manikas  Veronique Diéras  Thierry Delozier  Vladimir Vladimirov  Fatima Cardoso  Han Koh  Philippe Bougnoux  Corina E Dutcus  Seth Seegobin  Denis Mir  Nicole Meneses  Jantien Wanders  Chris Twelves  EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators  
  • PMID: 21376385
  •     318 citations


Background: Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a non-taxane microtubule dynamics inhibitor with a novel mode of action. We aimed to compare overall survival of heavily pretreated patients receiving eribulin versus currently available treatments.

Methods: In this phase 3 open-label study, women with locally recurrent or metastatic breast cancer were randomly allocated (2:1) to eribulin mesilate (1·4 mg/m(2) administered intravenously during 2-5 min on days 1 and 8 of a 21-day cycle) or treatment of physician's choice (TPC). Patients had received between two and five previous chemotherapy regimens (two or more for advanced disease), including an anthracycline and a taxane, unless contraindicated. Randomisation was stratified by geographical region, previous capecitabine treatment, and human epidermal growth factor receptor 2 status. Patients and investigators were not masked to treatment allocation. The primary endpoint was overall survival in the intention-to-treat population. This study is registered at, number NCT00388726.

Findings: 762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC). Overall survival was significantly improved in women assigned to eribulin (median 13·1 months, 95% CI 11·8-14·3) compared with TPC (10·6 months, 9·3-12·5; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·041). The most common adverse events in both groups were asthenia or fatigue (270 [54%] of 503 patients on eribulin and 98 [40%] of 247 patients on TPC at all grades) and neutropenia (260 [52%] patients receiving eribulin and 73 [30%] of those on TPC at all grades). Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.

Interpretation: Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer. This finding challenges the notion that improved overall survival is an unrealistic expectation during evaluation of new anticancer therapies in the refractory setting.

Funding: Eisai.

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
Daniel J Renouf, Patricia A Tang, +7 authors, Malcolm J Moore.
Invest New Drugs, 2011 Apr 29; 30(3). PMID: 21526355
Caroline M Perry.
Drugs, 2011 Jul 21; 71(10). PMID: 21770478
Current therapeutic strategies for invasive and metastatic bladder cancer.
Prakash Vishnu, Jacob Mathew, Winston W Tan.
Onco Targets Ther, 2011 Jul 28; 4. PMID: 21792316    Free PMC article.
Management options in triple-negative breast cancer.
Christina A Minami, Debra U Chung, Helena R Chang.
Breast Cancer (Auckl), 2011 Aug 25; 5. PMID: 21863131    Free PMC article.
Eribulin mesylate in patients with refractory cancers: a Phase I study.
Toru Mukohara, Shunji Nagai, +2 authors, Hironobu Minami.
Invest New Drugs, 2011 Sep 03; 30(5). PMID: 21887501    Free PMC article.
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
Alberto J Montero, Mauricio Escobar, +2 authors, Charles Vogel.
Curr Oncol Rep, 2011 Oct 21; 14(1). PMID: 22012632    Free PMC article.
Recent developments in treatment stratification for metastatic breast cancer.
Sarah Barton, Charles Swanton.
Drugs, 2011 Nov 01; 71(16). PMID: 22035512
Beyond taxanes: the next generation of microtubule-targeting agents.
Javier Cortes, Maria Vidal.
Breast Cancer Res Treat, 2011 Nov 25; 133(3). PMID: 22113255    Free PMC article.
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.
Eva Muñoz-Couselo, José Pérez-García, Javier Cortés.
Onco Targets Ther, 2011 Dec 14; 4. PMID: 22162924    Free PMC article.
Eribulin mesylate in the treatment of metastatic breast cancer.
Sarika Jain, Tessa Cigler.
Biologics, 2012 Feb 01; 6. PMID: 22291464    Free PMC article.
Major clinical research advances in gynecologic cancer in 2011.
Dong Hoon Suh, Kidong Kim, Jae Weon Kim.
J Gynecol Oncol, 2012 Feb 23; 23(1). PMID: 22355468    Free PMC article.
Current approaches to the management of Her2-negative metastatic breast cancer.
Keerthi Gogineni, Angela DeMichele.
Breast Cancer Res, 2012 Mar 21; 14(2). PMID: 22429313    Free PMC article.
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.
J P M Ayoub, Sh Verma, Su Verma.
Curr Oncol, 2012 Apr 20; 19(2). PMID: 22514495    Free PMC article.
Chemotherapy-resistant metastatic breast cancer.
Carrie Marquette, Lisle Nabell.
Curr Treat Options Oncol, 2012 Apr 25; 13(2). PMID: 22528367
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
L A Devriese, M Mergui-Roelvink, +8 authors, J H M Schellens.
Invest New Drugs, 2012 May 05; 31(2). PMID: 22555773
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.
Massimo Cristofanilli.
J Oncol, 2012 May 31; 2012. PMID: 22645612    Free PMC article.
The role of targeted therapy and biomarkers in breast cancer treatment.
Alison T Stopeck, Ursa Brown-Glaberman, +5 authors, Hope S Rugo.
Clin Exp Metastasis, 2012 Jun 14; 29(7). PMID: 22692561
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Lot A Devriese, Petronella Els O Witteveen, +10 authors, Jan H M Schellens.
Br J Clin Pharmacol, 2012 Jul 19; 75(2). PMID: 22803519    Free PMC article.
Progress against solid tumors in danger: the metastatic breast cancer example.
Javier Cortés, Emiliano Calvo, +9 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2012 Aug 29; 30(28). PMID: 22927522    Free PMC article.
A case of brain metastases from breast cancer treated with whole-brain radiotherapy and eribulin mesylate.
Carsten Nieder, Gro Aandahl, Astrid Dalhaug.
Case Rep Oncol Med, 2012 Sep 07; 2012. PMID: 22953094    Free PMC article.
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Carlo Palmieri, Constantine Alifrangis, +5 authors, R Charles Coombes.
Oncologist, 2012 Sep 25; 17(11). PMID: 23002126    Free PMC article.
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.
Amye J Tevaarwerk, Robert J Gray, +7 authors, Joseph A Sparano.
Cancer, 2012 Oct 16; 119(6). PMID: 23065954    Free PMC article.
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors.
Thierry Lesimple, Julien Edeline, +10 authors, Larisa Reyderman.
Invest New Drugs, 2012 Nov 13; 31(4). PMID: 23143778
Update on taxane development: new analogs and new formulations.
Jean A Yared, Katherine H R Tkaczuk.
Drug Des Devel Ther, 2012 Dec 20; 6. PMID: 23251087    Free PMC article.
Tubulin-targeting agent combination therapies: dosing schedule could matter.
Eric Solary.
Br J Pharmacol, 2013 Jan 16; 168(7). PMID: 23316995    Free PMC article.
Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer.
Belinda Seto.
Clin Transl Med, 2013 Feb 02; 1(1). PMID: 23369283    Free PMC article.
Dragon exploration system on marine sponge compounds interactions.
Sunil Sagar, Mandeep Kaur, Aleksandar Radovanovic, Vladimir B Bajic.
J Cheminform, 2013 Feb 19; 5(1). PMID: 23415072    Free PMC article.
Natural products: a continuing source of novel drug leads.
Gordon M Cragg, David J Newman.
Biochim Biophys Acta, 2013 Feb 23; 1830(6). PMID: 23428572    Free PMC article.
Highly Cited. Review.
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Eleni Andreopoulou, Joseph A Sparano.
Curr Breast Cancer Rep, 2013 Feb 27; 5(1). PMID: 23440080    Free PMC article.
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
E Anders Kolb, Richard Gorlick, +10 authors, Malcolm A Smith.
Pediatr Blood Cancer, 2013 Apr 05; 60(8). PMID: 23553917    Free PMC article.
Eribulin for advanced breast cancer: a drug evaluation.
Alaaeldin Shablak.
J Breast Cancer, 2013 Apr 18; 16(1). PMID: 23593076    Free PMC article.
Population pharmacokinetic-pharmacodynamic analysis for eribulin mesilate-associated neutropenia.
J G Coen van Hasselt, Anubha Gupta, +3 authors, Alwin D R Huitema.
Br J Clin Pharmacol, 2013 Apr 23; 76(3). PMID: 23601153    Free PMC article.
Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.
Shigehira Saji.
BioDrugs, 2013 May 10; 27(5). PMID: 23658121    Free PMC article.
Drug resistance and the role of combination chemotherapy in improving patient outcomes.
Denise A Yardley.
Int J Breast Cancer, 2013 Jul 19; 2013. PMID: 23864953    Free PMC article.
Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.
Linda T Vahdat, Agustin A Garcia, +5 authors, Joseph A Sparano.
Breast Cancer Res Treat, 2013 Jul 24; 140(2). PMID: 23877339    Free PMC article.
Newer therapies for the treatment of metastatic breast cancer: a clinical update.
Anjana Mohan, S Ponnusankar.
Indian J Pharm Sci, 2013 Oct 02; 75(3). PMID: 24082340    Free PMC article.
SEOM clinical guidelines for the management of metastatic breast cancer 2013.
A Llombart Cussac, J de la Haba Rodríguez, +3 authors, SEOM.
Clin Transl Oncol, 2013 Oct 24; 15(12). PMID: 24151043
The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.
Zarnie Lwin, Jonathan W Riess, David Gandara.
J Thorac Dis, 2013 Oct 29; 5 Suppl 5. PMID: 24163748    Free PMC article.
Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.
Raffaella Palumbo, Federico Sottotetti, +5 authors, Antonio Bernardo.
Ther Adv Med Oncol, 2013 Nov 02; 5(6). PMID: 24179488    Free PMC article.
Regression of brain metastases from breast cancer with eribulin: a case report.
Hiromichi Matsuoka, Junji Tsurutani, +4 authors, Kazuhiko Nakagawa.
BMC Res Notes, 2013 Dec 20; 6. PMID: 24350786    Free PMC article.
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.
J Menis, C Twelves.
Breast Cancer (Dove Med Press), 2011 Jan 01; 3. PMID: 24367180    Free PMC article.
Potential clinical applications of halichondrins in breast cancer and other neoplasms.
Vanesa Ortega, Javier Cortés.
Breast Cancer (Dove Med Press), 2012 Jan 01; 4. PMID: 24367189    Free PMC article.
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
T Yoshida, Y Ozawa, +8 authors, J Matsui.
Br J Cancer, 2014 Feb 27; 110(6). PMID: 24569463    Free PMC article.
Highly Cited.
Eribulin drug review.
Nishitha Shetty, Sudeep Gupta.
South Asian J Cancer, 2014 Mar 26; 3(1). PMID: 24665449    Free PMC article.
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Hyman Muss, Javier Cortes, +7 authors, Joyce O'Shaughnessy.
Oncologist, 2014 Apr 01; 19(4). PMID: 24682463    Free PMC article.
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
Kristi McIntyre, Joyce O'Shaughnessy, +5 authors, Linda T Vahdat.
Breast Cancer Res Treat, 2014 Apr 05; 146(2). PMID: 24699910    Free PMC article.
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
Vinay Prasad, Paul R Massey, Tito Fojo.
J Clin Oncol, 2014 Apr 09; 32(15). PMID: 24711558    Free PMC article.
Health economic aspects of breast cancer treatment: the compulsory health insurances' view.
Barbara Zimmer, Axel Heyll.
Breast Care (Basel), 2014 Apr 10; 8(1). PMID: 24715839    Free PMC article.
Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.
Teresa Gamucci, Andrea Michelotti, +15 authors, Patrizia Vici.
J Cancer, 2014 Apr 12; 5(5). PMID: 24723974    Free PMC article.
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.
Herbert H Loong, Winnie Yeo.
Onco Targets Ther, 2014 May 03; 7. PMID: 24790457    Free PMC article.
Neuropathic cancer pain: What we are dealing with? How to manage it?
Ece Esin, Suayib Yalcin.
Onco Targets Ther, 2014 May 03; 7. PMID: 24790459    Free PMC article.
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
Marta Bonotto, Lorenzo Gerratana, +9 authors, Fabio Puglisi.
Oncologist, 2014 May 06; 19(6). PMID: 24794159    Free PMC article.
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
Breast cancer and aging: results of the U13 conference breast cancer panel.
M F Barginear, H Muss, +5 authors, A Hurria.
Breast Cancer Res Treat, 2014 May 23; 146(1). PMID: 24847891    Free PMC article.
Oncology nursing support for safe and effective use of eribulin in metastatic breast cancer.
Diana Donovan, Laura Urquhart, +2 authors, Laura Moore.
Clin Med Insights Oncol, 2014 May 24; 8. PMID: 24855406    Free PMC article.
Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Ryuji Takahashi, Uhi Toh, +12 authors, Tetsuro Sasada.
Breast Cancer Res, 2014 Jul 06; 16(4). PMID: 24992895    Free PMC article.
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Yasuhiro Funahashi, Kiyoshi Okamoto, +15 authors, Yoshiya Oda.
Cancer Sci, 2014 Jul 26; 105(10). PMID: 25060424    Free PMC article.
Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.
Masato Terashima, Kazuko Sakai, +4 authors, Kazuto Nishio.
Springerplus, 2014 Aug 21; 3. PMID: 25140293    Free PMC article.
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Ann H Partridge, R Bryan Rumble, +11 authors, Ian E Smith.
J Clin Oncol, 2014 Sep 04; 32(29). PMID: 25185096    Free PMC article.
Highly Cited.
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Janette Greenhalgh, Adrian Bagust, +7 authors, Susan O'Reilly.
Pharmacoeconomics, 2014 Sep 13; 33(2). PMID: 25213036
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
F Cardoso, A Costa, +40 authors, E Winer.
Ann Oncol, 2014 Sep 23; 25(10). PMID: 25234545    Free PMC article.
Highly Cited.
Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer.
Hirofumi Mukai, Toshiaki Saeki, +6 authors, Yasutsuna Sasaki.
Invest New Drugs, 2014 Sep 23; 33(1). PMID: 25242374    Free PMC article.
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
M Koczywas, P H Frankel, +13 authors, E M Newman.
Br J Cancer, 2014 Oct 29; 111(12). PMID: 25349975    Free PMC article.
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, +13 authors, Susan M Domchek.
J Clin Oncol, 2014 Nov 05; 33(3). PMID: 25366685    Free PMC article.
Highly Cited.
Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.
Satoko Yamaguchi, Yoshiko Maida, +3 authors, Kenkichi Masutomi.
PLoS One, 2014 Nov 07; 9(11). PMID: 25375122    Free PMC article.
Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
Ashley M Laughney, Eunha Kim, +6 authors, Ralph Weissleder.
Sci Transl Med, 2014 Nov 08; 6(261). PMID: 25378644    Free PMC article.
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Chris Twelves, Javier Cortes, +4 authors, Ahmad Awada.
Breast Cancer Res Treat, 2014 Nov 09; 148(3). PMID: 25381136    Free PMC article.
Highly Cited.
Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis.
Danka J F Stuijver, Erica Romualdi, +4 authors, Alessandro Squizzato.
Intern Emerg Med, 2014 Dec 17; 10(2). PMID: 25502591
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Peter A Kaufman, Ahmad Awada, +7 authors, Javier Cortes.
J Clin Oncol, 2015 Jan 22; 33(6). PMID: 25605862    Free PMC article.
Highly Cited.
Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy.
Mark K Doherty, Patrick G Morris.
Int J Womens Health, 2015 Jan 23; 7. PMID: 25610001    Free PMC article.
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
T Sakiyama, J Tsurutani, +9 authors, K Nakagawa.
Br J Cancer, 2015 Feb 06; 112(5). PMID: 25654665    Free PMC article.
Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.
Manuel Segura-González, Miguel Quintana-Quintana.
Med Oncol, 2015 Feb 28; 32(4). PMID: 25720523
Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.
Nicholas F Dybdal-Hargreaves, April L Risinger, Susan L Mooberry.
Clin Cancer Res, 2015 Apr 04; 21(11). PMID: 25838395    Free PMC article.
Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.
A A Joy, M Ghosh, R Fernandes, M J Clemons.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848337    Free PMC article.
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Iben Kümler, Eva Balslev, +2 authors, Dorte Nielsen.
BMC Cancer, 2015 Apr 18; 15. PMID: 25885574    Free PMC article.
Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.
Satoshi Morita, Kentaro Sakamaki, Guosheng Yin.
J Natl Cancer Inst, 2015 May 10; 107(8). PMID: 25956357    Free PMC article.
Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?
Marta Bonotto, Lorenzo Gerratana, +4 authors, Fabio Puglisi.
Oncologist, 2015 May 29; 20(7). PMID: 26018662    Free PMC article.
Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series.
Alex Y Chang, Xu Xiao Ying.
Breast Cancer (Auckl), 2015 Jun 09; 9. PMID: 26052228    Free PMC article.
Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy?
A Schneeweiss, E Ruckhäberle, J Huober.
Geburtshilfe Frauenheilkd, 2015 Jul 15; 75(6). PMID: 26166838    Free PMC article.
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.
Holly G Prigerson, Yuhua Bao, +9 authors, Paul K Maciejewski.
JAMA Oncol, 2015 Jul 24; 1(6). PMID: 26203912    Free PMC article.
Highly Cited.
Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.
Takayo Fukuda, Masahiko Tanabe, +4 authors, Yoshinori Ito.
Springerplus, 2015 Jul 29; 4. PMID: 26217553    Free PMC article.
Eribulin in Cancer Treatment.
Umang Swami, Umang Shah, Sanjay Goel.
Mar Drugs, 2015 Aug 12; 13(8). PMID: 26262627    Free PMC article.
PARP inhibitors in the management of breast cancer: current data and future prospects.
Luca Livraghi, Judy E Garber.
BMC Med, 2015 Aug 14; 13. PMID: 26268938    Free PMC article.
Highly Cited. Review.
CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
Jingyu Xiang, Michelle A Hurchla, +17 authors, Katherine N Weilbaecher.
Mol Cancer Ther, 2015 Aug 14; 14(11). PMID: 26269605    Free PMC article.
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
Michael S Isakoff, Stefan S Bielack, Paul Meltzer, Richard Gorlick.
J Clin Oncol, 2015 Aug 26; 33(27). PMID: 26304877    Free PMC article.
Highly Cited. Review.
Eribulin for heavily pre-treated metastatic breast cancer patients.
Antonia Digklia, Ioannis A Voutsadakis.
World J Exp Med, 2015 Aug 27; 5(3). PMID: 26309821    Free PMC article.
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Robert J Morgan, Timothy W Synold, +9 authors, Edward M Newman.
Cancer Chemother Pharmacol, 2015 Sep 13; 76(5). PMID: 26362045    Free PMC article.
Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies.
Joyce O'Shaughnessy, Kristi McIntyre, +5 authors, Linda Vahdat.
Springerplus, 2015 Sep 29; 4. PMID: 26413438    Free PMC article.
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
Mélodie Dell'Ova, Eléonora De Maio, +7 authors, Stéphane Pouderoux.
BMC Cancer, 2015 Oct 10; 15. PMID: 26449988    Free PMC article.
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
Qiao Li, Qing Li, +7 authors, Binghe Xu.
Cancer Biol Ther, 2015 Oct 16; 16(12). PMID: 26466918    Free PMC article.
Eribulin targets a ch-TOG-dependent directed migration of cancer cells.
Brice Chanez, Anthony Gonçalves, Ali Badache, Pascal Verdier-Pinard.
Oncotarget, 2015 Oct 27; 6(39). PMID: 26497677    Free PMC article.
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.
Matthew Trendowski.
Drugs, 2015 Oct 27; 75(17). PMID: 26501980    Free PMC article.
Case Studies in the Management of Metastatic Breast Cancer with Eribulin.
Sharon Wilks, Kristi McIntyre.
Clin Med Insights Oncol, 2015 Oct 29; 9. PMID: 26508896    Free PMC article.
Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.
Junichiro Watanabe.
Springerplus, 2015 Nov 07; 4. PMID: 26543760    Free PMC article.
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
S Lheureux, A M Oza, +9 authors, R Goel.
Br J Cancer, 2015 Nov 12; 113(11). PMID: 26554651    Free PMC article.
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.
Javier Cortes, Stacie Hudgens, +7 authors, Galina Velikova.
Breast Cancer Res Treat, 2015 Nov 15; 154(3). PMID: 26567010    Free PMC article.
SEOM clinical guidelines in metastatic breast cancer 2015.
J Gavilá, S Lopez-Tarruella, +7 authors, M Martin.
Clin Transl Oncol, 2015 Dec 20; 17(12). PMID: 26683474    Free PMC article.
Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings.
Victor C Kok.
Breast Cancer (Auckl), 2015 Dec 23; 9. PMID: 26691012    Free PMC article.
Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin.
Suee Lee, Sung Yong Oh, +5 authors, Hyo-Jin Kim.
J Breast Cancer, 2016 Jan 16; 18(4). PMID: 26770248    Free PMC article.
Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.
Ornella Garrone, Filippo Montemurro, +10 authors, Marco Carlo Merlano.
Springerplus, 2016 Feb 03; 5. PMID: 26835238    Free PMC article.
Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer.
Takayoshi Kiba, Nao Morii, +5 authors, Hiroyasu Yamashiro.
Mol Clin Oncol, 2016 Feb 13; 4(1). PMID: 26870356    Free PMC article.
Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.
M B Hannouf, E Winquist, +6 authors, G S Zaric.
Pharmacogenomics J, 2016 Mar 30; 17(3). PMID: 27019982
A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.
Tsutomu Takashima, Shinya Tokunaga, +16 authors, Kosei Hirakawa.
Springerplus, 2016 Mar 31; 5. PMID: 27026861    Free PMC article.
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer.
Simon B Zeichner, Hiromi Terawaki, Keerthi Gogineni.
Breast Cancer (Auckl), 2016 Apr 05; 10. PMID: 27042088    Free PMC article.
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
Jungsil Ro, Fiona Tsui-Fen Cheng, +5 authors, Asian Working Group for Eribulin Clinical Guide.
J Breast Cancer, 2016 Apr 12; 19(1). PMID: 27066091    Free PMC article.
Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Kenichi Inoue, Tsuyoshi Saito, +7 authors, Masafumi Kurosumi.
Breast Cancer Res Treat, 2016 Apr 30; 157(2). PMID: 27125669    Free PMC article.
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
X Pivot, F Marmé, +3 authors, A Wolfer.
Ann Oncol, 2016 May 15; 27(8). PMID: 27177860    Free PMC article.
Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Varvara K Kozyreva, Anna A Kiseleva, +16 authors, Elena N Pugacheva.
Mol Cancer Ther, 2016 May 29; 15(8). PMID: 27235164    Free PMC article.
Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.
Keiichi Kontani, Shin-Ichiro Hashimoto, +8 authors, Hiroyasu Yokomise.
Mol Clin Oncol, 2016 Jun 11; 4(6). PMID: 27284428    Free PMC article.
Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
J A Mestres, A B iMolins, +17 authors, P Sanchez-Rovira.
Clin Transl Oncol, 2016 Jun 18; 19(2). PMID: 27314861    Free PMC article.
Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.
Ina Jazić, Deborah Schrag, Daniel J Sargent, Sebastien Haneuse.
J Natl Cancer Inst, 2016 Jul 07; 108(12). PMID: 27381741    Free PMC article.
Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports.
Kyung-Do Byun, Sung Gwe Ahn, +9 authors, Tae Hyun Kim.
J Breast Cancer, 2016 Jul 07; 19(2). PMID: 27382400    Free PMC article.
Compounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cells.
Ana Zovko, Metka Novak, +7 authors, Kristina Viktorsson.
Oncotarget, 2016 Jul 08; 7(31). PMID: 27384680    Free PMC article.
Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
Takayuki Kobayashi, Jyunichi Tomomatsu, +6 authors, Shunji Takahashi.
BMC Cancer, 2016 Jul 09; 16. PMID: 27389013    Free PMC article.
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.
Christopher Twelves, Javier Cortes, +8 authors, Edith A Perez.
Breast Cancer Res, 2015 Jan 01; 17(1). PMID: 27391598    Free PMC article.
Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
Chris Twelves, Ahmad Awada, +6 authors, Peter A Kaufman.
Breast Cancer (Auckl), 2016 Jul 12; 10. PMID: 27398025    Free PMC article.
Metastatic breast cancer: The Odyssey of personalization.
A Sonnenblick, N Pondé, M Piccart.
Mol Oncol, 2016 Jul 20; 10(8). PMID: 27430154    Free PMC article.
An update on clinical oncology for the non-oncologist.
Rafael Aliosha Kaliks.
Einstein (Sao Paulo), 2016 Jul 28; 14(2). PMID: 27462901    Free PMC article.
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
Yeon Hee Park, Tae Yong Kim, +17 authors, Kyung Hae Jung.
Cancer Res Treat, 2016 Aug 05; 49(2). PMID: 27488876    Free PMC article.
ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Takaaki Oba, Hiroto Izumi, Ken-Ichi Ito.
Oncotarget, 2016 Sep 03; 7(43). PMID: 27588398    Free PMC article.
Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Colin Thomas, Sujana Movva.
Onco Targets Ther, 2016 Sep 28; 9. PMID: 27672333    Free PMC article.
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
Jonathan Noujaim, Salma Alam, Khin Thway, Robin Lewis Jones.
Indian J Med Paediatr Oncol, 2016 Oct 01; 37(3). PMID: 27688604    Free PMC article.
Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.
Francesco Giotta, Luigi Acito, +16 authors, Patrizia Zucchinelli.
Oncologist, 2016 Oct 16; 21(11). PMID: 27742906    Free PMC article.
Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Hiroko Kitahara, Mariko Hirai, +3 authors, Shuichi Kawashiri.
Oncol Rep, 2016 Oct 26; 36(6). PMID: 27779690    Free PMC article.
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.
Alessandro De Vita, Laura Mercatali, +8 authors, Toni Ibrahim.
Onco Targets Ther, 2016 Oct 28; 9. PMID: 27785071    Free PMC article.
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Hikmat Abdel-Razeq.
Cancer Manag Res, 2016 Nov 02; 8. PMID: 27799819    Free PMC article.
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.
Barbara Kiesewetter, Markus Raderer, +8 authors, Christoph C Zielinski.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843624    Free PMC article.
Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
Valerie B Sampson, Nancy S Vetter, +5 authors, Edward A Kolb.
Oncotarget, 2016 Nov 20; 7(52). PMID: 27863409    Free PMC article.
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.
Shannon Puhalla, Sharon Wilks, +5 authors, Linda Vahdat.
Breast Cancer (Dove Med Press), 2016 Dec 21; 8. PMID: 27994483    Free PMC article.
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
Shinichiro Kashiwagi, Yuka Asano, +9 authors, Masaichi Ohira.
PLoS One, 2017 Feb 07; 12(2). PMID: 28166544    Free PMC article.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
F Cardoso, A Costa, +42 authors, E Winer.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177437    Free PMC article.
Highly Cited.
Efficacy of eribulin in breast cancer: a short report on the emerging new data.
Gelareh Eslamian, Caroline Wilson, Robin J Young.
Onco Targets Ther, 2017 Mar 01; 10. PMID: 28243113    Free PMC article.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Kenji Tamura, Kenichi Inoue, +19 authors, Yasuhiro Fujiwara.
Cancer Sci, 2017 Mar 04; 108(5). PMID: 28256066    Free PMC article.
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
Alexander T J Lee, Seth M Pollack, Paul Huang, Robin L Jones.
Curr Treat Options Oncol, 2017 Mar 24; 18(3). PMID: 28332083    Free PMC article.
A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study.
Brice Chanez, François Bertucci, +5 authors, Jean-Luc Raoul.
Support Care Cancer, 2017 Mar 30; 25(9). PMID: 28353038
Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.
A Aggarwal, T Fojo, +2 authors, R Sullivan.
Ann Oncol, 2017 Apr 30; 28(8). PMID: 28453615    Free PMC article.
Emerging therapies for breast cancer.
Xichun Hu, Wei Huang, Minhao Fan.
J Hematol Oncol, 2017 Apr 30; 10(1). PMID: 28454587    Free PMC article.
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Maura N Dickler, Sara M Tolaney, +11 authors, José Baselga.
Clin Cancer Res, 2017 May 24; 23(17). PMID: 28533223    Free PMC article.
Highly Cited.
Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Ravin Ratan, Shreyaskumar R Patel.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534249
Design, synthesis, and structure-activity relationships of pyrimido[4,5-b]indole-4-amines as microtubule depolymerizing agents that are effective against multidrug resistant cells.
Ravi Kumar Vyas Devambatla, Wei Li, +4 authors, Aleem Gangjee.
Bioorg Med Chem Lett, 2017 Jun 15; 27(15). PMID: 28610978    Free PMC article.
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Junichiro Watanabe, Yoshinori Ito, +15 authors, Toshiaki Saeki.
Invest New Drugs, 2017 Jul 01; 35(6). PMID: 28660549    Free PMC article.
Eribulin shows high concentration and long retention in xenograft tumor tissues.
Michiko Sugawara, Krista Condon, +4 authors, W George Lai.
Cancer Chemother Pharmacol, 2017 Jul 01; 80(2). PMID: 28664226    Free PMC article.
Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.
Toshihiro Tanaka, Miho Ueno, +7 authors, Yasushi Takamatsu.
Thorac Cancer, 2017 Jul 26; 8(5). PMID: 28741868    Free PMC article.
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Thomas Decker, Friedrich Overkamp, +5 authors, Tanja Trarbach.
BMC Cancer, 2017 Jul 27; 17(1). PMID: 28743247    Free PMC article.
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Michele Orditura, Adriano Gravina, +21 authors, Fortunato Ciardiello.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761747    Free PMC article.
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.
Gino K In, James S Hu, William W Tseng.
Ther Adv Med Oncol, 2017 Aug 11; 9(8). PMID: 28794805    Free PMC article.
Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
Shinichiro Kashiwagi, Wakaba Fukushima, +8 authors, Masaichi Ohira.
BMC Cancer, 2017 Sep 02; 17(1). PMID: 28859615    Free PMC article.
Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
Masaya Hattori, Hiroshi Ishiguro, +6 authors, Hiroji Iwata.
Breast Cancer, 2017 Sep 02; 25(1). PMID: 28861862    Free PMC article.
Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.
Ken Ito, Shusei Hamamichi, +9 authors, Hirofumi Fujii.
Cancer Sci, 2017 Sep 05; 108(11). PMID: 28869796    Free PMC article.
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.
N Katakami, E Felip, +8 authors, F Barlesi.
Ann Oncol, 2017 Sep 16; 28(9). PMID: 28911085    Free PMC article.
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
Courtney Davis, Huseyin Naci, +3 authors, Ajay Aggarwal.
BMJ, 2017 Oct 06; 359. PMID: 28978555    Free PMC article.
Highly Cited.
Marine Sponge Natural Products with Anticancer Potential: An Updated Review.
Cinzia Calcabrini, Elena Catanzaro, +2 authors, Carmela Fimognari.
Mar Drugs, 2017 Oct 14; 15(10). PMID: 29027954    Free PMC article.
Development of interstitial pneumonia during treatment with eribulin: a case report.
Kota Nakamura, Motoyasu Kato, +4 authors, Kazuhisa Takahashi.
BMC Res Notes, 2017 Nov 08; 10(1). PMID: 29110735    Free PMC article.
Production, in Pichia pastoris, of a recombinant monomeric mapacalcine, a protein with anti-ischemic properties.
A Noubhani, D Bégu, +8 authors, M Hugues.
Biochem Biophys Rep, 2015 Oct 09; 4. PMID: 29124217    Free PMC article.
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.
Shreyas S Rao, Jenna Stoehr, +8 authors, Jacqueline S Jeruss.
Oncotarget, 2017 Nov 16; 8(48). PMID: 29137393    Free PMC article.
Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.
Sabrina Rossi, Alessandra Cassano, +4 authors, Carlo Barone.
Drugs Context, 2017 Nov 24; 6. PMID: 29167692    Free PMC article.
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
Sakura Iizumi, Tatsunori Shimoi, +9 authors, Kenji Tamura.
BMC Cancer, 2017 Dec 06; 17(1). PMID: 29202787    Free PMC article.
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Renaud Sabatier, Véronique Diéras, +10 authors, Anthony Gonçalves.
Cancer Res Treat, 2017 Dec 29; 50(4). PMID: 29281873    Free PMC article.
Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years.
Jianrong Zhang, Yiyin Zhang, +13 authors, Jianxing He.
Ann Transl Med, 2018 Jan 05; 5(24). PMID: 29299443    Free PMC article.
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
Xavier Pivot, Seock Ah Im, Matthew Guo, Frederik Marmé.
Breast Cancer, 2018 Jan 06; 25(3). PMID: 29302858    Free PMC article.
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.
Ling Peng, Yun Hong, +4 authors, Qiong Zhao.
Oncotarget, 2018 Jan 18; 8(67). PMID: 29340112    Free PMC article.
Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents.
Catherine Terret, Chiara Russo.
Drugs Aging, 2018 Feb 02; 35(2). PMID: 29388072
Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib.
V Sgroi, M Bassanelli, +5 authors, P Marchetti.
Exp Hematol Oncol, 2018 Feb 09; 7. PMID: 29416938    Free PMC article.
Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Shoichiro Ohtani, Takahiro Nakayama, +14 authors, Norikazu Masuda.
Breast Cancer, 2018 Feb 13; 25(4). PMID: 29435730    Free PMC article.
Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.
Nicholas F Dybdal-Hargreaves, April L Risinger, Susan L Mooberry.
Oncotarget, 2018 Feb 22; 9(5). PMID: 29464017    Free PMC article.
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.
Shinichiro Kashiwagi, Gen Tsujio, +10 authors, Masaichi Ohira.
J Transl Med, 2018 Mar 11; 16(1). PMID: 29523158    Free PMC article.
Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
Barbara A Helfrich, Dexiang Gao, Paul A Bunn.
Lung Cancer, 2018 Mar 25; 118. PMID: 29571994    Free PMC article.
Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.
Yasutaka Tono, Mikiya Ishihara, +8 authors, Naoyuki Katayama.
Oncotarget, 2018 Mar 31; 9(19). PMID: 29599915    Free PMC article.
The importance of greater speed in drug development for advanced malignancies.
David J Stewart, Andrew A Stewart, +7 authors, Razelle Kurzrock.
Cancer Med, 2018 Mar 31; 7(5). PMID: 29601671    Free PMC article.
Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Kun-Ming Rau, Fu Ou-Yang, +15 authors, Ming-Feng Hou.
Breast Cancer Res Treat, 2018 Apr 07; 170(3). PMID: 29623575    Free PMC article.
The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Jianhong Yang, Wei Yan, +17 authors, Lijuan Chen.
J Biol Chem, 2018 Apr 25; 293(24). PMID: 29691282    Free PMC article.
Toward Generalization of Iterative Small Molecule Synthesis.
Jonathan W Lehmann, Daniel J Blair, Martin D Burke.
Nat Rev Chem, 2018 Apr 27; 2(2). PMID: 29696152    Free PMC article.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Eric S Schafer, Rachel E Rau, +11 authors, Susan M Blaney.
Pediatr Blood Cancer, 2018 May 03; 65(8). PMID: 29719113    Free PMC article.
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.
Daniel G Stover, Carlos R Gil Del Alcazar, +15 authors, Nancy U Lin.
NPJ Breast Cancer, 2018 May 16; 4. PMID: 29761158    Free PMC article.
Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
Takaaki Oba, Ken-Ichi Ito.
Oncotarget, 2018 May 26; 9(33). PMID: 29796167    Free PMC article.
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Karen A Cadoo, Peter A Kaufman, +3 authors, Tiffany A Traina.
Clin Breast Cancer, 2018 Jun 14; 18(6). PMID: 29895438    Free PMC article.
Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
J Lemieux, S Audet.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910659    Free PMC article.
Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.
Kenichi Inoue, Jun Ninomiya, +2 authors, Masafumi Kurosumi.
BMC Cancer, 2018 Jun 22; 18(1). PMID: 29925345    Free PMC article.
Pharmacodynamic analysis of eribulin safety in breast cancer patients using real-world postmarketing surveillance data.
Takahisa Kawamura, Hidefumi Kasai, +5 authors, Yusuke Tanigawara.
Cancer Sci, 2018 Jun 23; 109(9). PMID: 29933506    Free PMC article.
Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Tetsu Hayashida, Hiromitsu Jinno, +12 authors, Yuko Kitagawa.
BMC Cancer, 2018 Jun 30; 18(1). PMID: 29954362    Free PMC article.
Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement.
Lorenzo Dottorini, Laura Catena, +3 authors, Emilio Bajetta.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036862    Free PMC article.
Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.
Marta Medici, Emanuela Fossile.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036863    Free PMC article.
Eribulin in "Field Practice": More from the Italian Experience.
Giulia Valeria Bianchi.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036866    Free PMC article.
Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study.
Rebecca Pedersini, Lucia Vassalli, +7 authors, Alfredo Berruti.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036867    Free PMC article.
Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.
Raffaele Nettuno, Carmine Menditto.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036877    Free PMC article.
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.
Rita De Sanctis, Elisa Agostinetto, +7 authors, Armando Santoro.
Oncology, 2018 Jul 24; 94 Suppl 1. PMID: 30036884    Free PMC article.
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
Giovanna Catania, Paola Malaguti, +3 authors, Alessandra Fabi.
Oncology, 2018 Jul 25; 94 Suppl 1. PMID: 30041177    Free PMC article.
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports.
Guido Giordano, Antonio Febbraro, +6 authors, The Italian Eribulin Working Group.
Oncology, 2018 Jul 25; 94 Suppl 1. PMID: 30041178    Free PMC article.
Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience.
B J Srinivasa, Bhanu Prakash Lalkota, +9 authors, Radheshyam Naik.
Clin Med Insights Oncol, 2018 Jul 27; 12. PMID: 30046259    Free PMC article.
Differential Morphological and Biochemical Recovery from Chemotherapy-Induced Peripheral Neuropathy Following Paclitaxel, Ixabepilone, or Eribulin Treatment in Mouse Sciatic Nerves.
B M Cook, K M Wozniak, +7 authors, Stuart C Feinstein.
Neurotox Res, 2018 Jul 28; 34(3). PMID: 30051419
Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
Sarah S Mougalian, Ronda Copher, +6 authors, Bruce A Feinberg.
Cancer Med, 2018 Aug 02; 7(9). PMID: 30066497    Free PMC article.
Outcome of eribulin as a late treatment line for Thai metastatic breast cancer patients.
Chagkrit Ditsatham, Imjai Chitapanarux, +8 authors, Patumrat Sripan.
Onco Targets Ther, 2018 Aug 15; 11. PMID: 30104885    Free PMC article.
Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
Jean-David Fumet, Mark Wickre, +4 authors, Erika Viel.
BMC Cancer, 2018 Aug 22; 18(1). PMID: 30126360    Free PMC article.
Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil.
Toru Kurata, Sachio Fushida, +7 authors, Tetsuo Ohta.
Cancer Manag Res, 2018 Aug 28; 10. PMID: 30147370    Free PMC article.
A case of undifferentiated pleomorphic sarcoma of the breast with lung and bone metastases.
Haruhiko Yamazaki, Satoru Shimizu, +5 authors, Munetaka Masuda.
Int J Surg Case Rep, 2018 Aug 31; 51. PMID: 30165321    Free PMC article.
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.
Jianrong Zhang, Yiyin Zhang, +18 authors, Jianxing He.
BMJ Open, 2018 Sep 13; 8(9). PMID: 30206071    Free PMC article.
Profile of abemaciclib and its potential in the treatment of breast cancer.
James M Martin, Lori J Goldstein.
Onco Targets Ther, 2018 Sep 15; 11. PMID: 30214230    Free PMC article.
Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells.
Martin Leutenegger, Ramona Bruckner, +3 authors, Michael Scharl.
Inflamm Intest Dis, 2018 Sep 18; 2(4). PMID: 30221148    Free PMC article.
Reconsideration of sample size and power calculation for overall survival in cancer clinical trials.
Inkyung Jung, Hee Jung Ko, Sun Young Rha, Chung Mo Nam.
Contemp Clin Trials Commun, 2018 Oct 12; 12. PMID: 30302417    Free PMC article.
CXCR4 antagonists for treatment of breast cancer.
Javier Cortés, Esther Holgado, Jose Perez-Garcia.
Oncotarget, 2018 Oct 17; 9(71). PMID: 30323888    Free PMC article.
Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Yoshiya Horimoto, Emi Tokuda, +8 authors, Mitsue Saito.
J Transl Med, 2018 Oct 22; 16(1). PMID: 30342534    Free PMC article.
Anti-proliferative and anti-inflammatory activities of the sea cucumber Holothuria polii aqueous extract.
Mike Kareh, Rana El Nahas, +5 authors, Rabih Talhouk.
SAGE Open Med, 2018 Nov 21; 6. PMID: 30455947    Free PMC article.
Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
Eisuke Kobayashi, Yoichi Naito, +5 authors, Akira Kawai.
Jpn J Clin Oncol, 2019 Aug 01; 49(10). PMID: 31365116    Free PMC article.
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysis.
Junpeng Wang, Xin Li, +6 authors, Tianzhong Yan.
EBioMedicine, 2019 Aug 24; 47. PMID: 31439476    Free PMC article.
Marine Natural Products: A Source of Novel Anticancer Drugs.
Shaden A M Khalifa, Nizar Elias, +13 authors, Hesham R El-Seedi.
Mar Drugs, 2019 Aug 25; 17(9). PMID: 31443597    Free PMC article.
Highly Cited. Review.
Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wei Wen, Emily Marcinkowski, +11 authors, John H Yim.
Cells, 2019 Sep 05; 8(9). PMID: 31480338    Free PMC article.
Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner.
Roma Kaul, April L Risinger, Susan L Mooberry.
Br J Cancer, 2019 Sep 05; 121(7). PMID: 31481735    Free PMC article.
Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
Tsutomu Iwasa, Junji Tsurutani, +13 authors, Kazuhiko Nakagawa.
BMC Cancer, 2019 Oct 18; 19(1). PMID: 31619197    Free PMC article.
Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Jin Sun Lee, Susan E Yost, +14 authors, Yuan Yuan.
Breast Cancer Res, 2019 Nov 11; 21(1). PMID: 31703728    Free PMC article.
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.
Laura Pizzuti, Eriseld Krasniqi, +16 authors, Patrizia Vici.
J Cancer, 2019 Nov 26; 10(24). PMID: 31762800    Free PMC article.
Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Milana Bergamino Sirvén, Adela Fernández-Ortega, +9 authors, Sonia Pernas.
BMC Pharmacol Toxicol, 2019 Nov 23; 20(1). PMID: 31753013    Free PMC article.
Clinical Implications of Extracellular HMGA1 in Breast Cancer.
Olga Méndez, José Pérez, +3 authors, Josep Villanueva.
Int J Mol Sci, 2019 Nov 30; 20(23). PMID: 31779212    Free PMC article.
Bone Metastasis: Current State of Play.
Anthony Turpin, Martine Duterque-Coquillaud, Marie-Hélène Vieillard.
Transl Oncol, 2019 Dec 27; 13(2). PMID: 31877463    Free PMC article.
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study.
Vincenzo Adamo, Giuseppina Rosaria Rita Ricciardi, +14 authors, Michele Caruso.
Ther Adv Med Oncol, 2020 Jan 07; 11. PMID: 31903098    Free PMC article.
Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.
Joanna Gotfrit, John J W Shin, +2 authors, Paul Wheatley-Price.
Oncologist, 2019 Sep 12; 25(1). PMID: 31506392    Free PMC article.
Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies.
Mitsuhiro Furuta, Junichiro Watanabe, +2 authors, Hirofumi Yasui.
In Vivo, 2019 Dec 29; 34(1). PMID: 31882489    Free PMC article.
Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653).
Sarmad Sadeghi, Susan G Groshen, +9 authors, Primo N Lara.
J Clin Oncol, 2019 Aug 08; 37(29). PMID: 31390274    Free PMC article.
Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.
Natsuko Satomi-Tsushita, Akihiko Shimomura, +9 authors, Kenji Tamura.
PLoS One, 2019 Sep 05; 14(9). PMID: 31483849    Free PMC article.
Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature.
William T Tran, Carolina Ibáñez, +3 authors, Tomas Merino.
Ecancermedicalscience, 2020 Feb 28; 14. PMID: 32104208    Free PMC article.
Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study.
Manabu Murakami, Hiroaki Kanemura, +2 authors, Tomohide Tamura.
Intern Med, 2019 Oct 08; 59(4). PMID: 31588076    Free PMC article.
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elena Elez, Carlos Gomez-Roca, +10 authors, Jean-Pierre Delord.
Invest New Drugs, 2018 Nov 10; 37(4). PMID: 30411218
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.
Silvana Leo, Ermenegildo Arnoldi, +18 authors, Laura Biganzoli.
Oncologist, 2018 Nov 11; 24(6). PMID: 30413667    Free PMC article.
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
T R Jeffry Evans, Emma Dean, +11 authors, Rebecca Kristeleit.
Br J Cancer, 2019 Jan 27; 120(4). PMID: 30679780    Free PMC article.
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Chris Twelves, Alan Anthoney, +9 authors, T R Jeffry Evans.
Br J Cancer, 2019 Feb 21; 120(6). PMID: 30783204    Free PMC article.
Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Kenichi Inoue, Jun Ninomiya, +6 authors, SBCCSG-36 investigators.
Invest New Drugs, 2019 Mar 09; 37(3). PMID: 30848403    Free PMC article.
Covalent modification of Cys-239 in β-tubulin by small molecules as a strategy to promote tubulin heterodimer degradation.
Jianhong Yang, Yong Li, +4 authors, Lijuan Chen.
J Biol Chem, 2019 Apr 04; 294(20). PMID: 30940730    Free PMC article.
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
Ji-Yeon Kim, Seri Park, +18 authors, Korean Cancer Study Group.
Cancer Commun (Lond), 2019 May 30; 39(1). PMID: 31138332    Free PMC article.
Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
Akihiko Shimomura, Kan Yonemori, +16 authors, Kenji Tamura.
Transl Oncol, 2019 Aug 06; 12(10). PMID: 31382135    Free PMC article.
N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study.
Takaaki Masuda, Hiroki Ueo, +12 authors, Hiroaki Ueo.
Int J Mol Sci, 2020 Jan 18; 21(2). PMID: 31947504    Free PMC article.
Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
José Pérez-Garcia, Javier Cortés, Otto Metzger Filho.
Oncologist, 2018 Dec 24; 24(8). PMID: 30578311    Free PMC article.
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
Serena Di Cosimo, Nicla La Verde, +16 authors, Filippo de Braud.
PLoS One, 2019 Aug 08; 14(8). PMID: 31390375    Free PMC article.
From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.
Edina Wang, Maria Alba Sorolla, Priya Darshini Gopal Krishnan, Anabel Sorolla.
Biomolecules, 2020 Feb 12; 10(2). PMID: 32041255    Free PMC article.
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Jodi A Kagihara, Michelle Andress, Jennifer R Diamond.
Expert Rev Precis Med Drug Dev, 2020 Mar 20; 5(2). PMID: 32190733    Free PMC article.
Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months.
Sukesh Manthri, Purva Sharma, +2 authors, Devapiran Jaishankar.
Cureus, 2020 Mar 24; 12(2). PMID: 32201658    Free PMC article.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Claudio Vernieri, Michele Prisciandaro, +18 authors, Filippo de Braud.
Cancers (Basel), 2020 Mar 12; 12(3). PMID: 32155941    Free PMC article.
Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer.
Takaaki Fujii, Shoko Tokuda, +4 authors, Ken Shirabe.
In Vivo, 2020 Mar 01; 34(2). PMID: 32111804    Free PMC article.
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer.
Sumito Shingaki, Takahiro Kogawa, +10 authors, Toru Mukohara.
J Cancer, 2020 May 06; 11(14). PMID: 32368292    Free PMC article.
Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).
Mark N Stein, Yu-Hui Chen, +7 authors, Robert S DiPaola.
Am J Clin Oncol, 2019 Feb 23; 42(4). PMID: 30789412    Free PMC article.
Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Toshinari Yamashita, Norikazu Masuda, +16 authors, Shinji Ohno.
Trials, 2020 May 10; 21(1). PMID: 32381018    Free PMC article.
Chemotherapy use near the end-of-life in patients with metastatic breast cancer.
Luisa Edman Kessler, Johnny Sigfridsson, +4 authors, Alexios Matikas.
Breast Cancer Res Treat, 2020 May 10; 181(3). PMID: 32383058    Free PMC article.
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients.
Fabienne Schochter, Kim Werner, +11 authors, Lisa Wiesmüller.
Cancers (Basel), 2020 Apr 15; 12(4). PMID: 32283863    Free PMC article.
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Takahiro Kogawa, Takeo Fujii, +12 authors, Naoto T Ueno.
Oncologist, 2020 Feb 01; 25(6). PMID: 32003919    Free PMC article.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, +14 authors, Shunji Takahashi.
J Clin Oncol, 2020 Feb 15; 38(17). PMID: 32058843    Free PMC article.
Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Andrew J Robles, Raushan T Kurmasheva, +7 authors, Peter J Houghton.
Clin Cancer Res, 2020 Mar 19; 26(12). PMID: 32184294    Free PMC article.
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Yasuo Miyoshi, Yuta Yoshimura, +9 authors, Javier Cortes.
Breast Cancer, 2020 Mar 07; 27(4). PMID: 32133606    Free PMC article.
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.
Giuseppe Badalamenti, Carlo Messina, +3 authors, Lorena Incorvaia.
Radiol Med, 2018 Apr 06; 124(4). PMID: 29619613
Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.
Joyce O'Shaughnessy, Javier Cortes, +5 authors, Takayuki Ueno.
Sci Rep, 2020 Jul 10; 10(1). PMID: 32641747    Free PMC article.
Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.
Michael Lattanzi, Arjun V Balar.
Curr Oncol Rep, 2019 Feb 27; 21(3). PMID: 30806823
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
Adam S Komorowski, Helen J MacKay, Rossanna C Pezo.
Cancer Med, 2020 May 27; 9(14). PMID: 32452660    Free PMC article.
Systematic Review.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Lillian M Smyth, Kenji Tamura, +25 authors, David M Hyman.
Clin Cancer Res, 2020 Apr 22; 26(15). PMID: 32312891    Free PMC article.
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience.
Eufemia S Lutrino, Laura Orlando, +17 authors, Saverio Cinieri.
Tumori, 2019 Dec 19; 106(4). PMID: 31847742    Free PMC article.
Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial.
Angelos Koutras, Flora Zagouri, +13 authors, George Fountzilas.
Br J Cancer, 2020 Jun 04; 123(3). PMID: 32488135    Free PMC article.
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.
Jennifer L Caswell-Jin, Sylvia K Plevritis, +6 authors, Allison W Kurian.
JNCI Cancer Spectr, 2019 Jan 11; 2(4). PMID: 30627694    Free PMC article.
Malignant Brenner tumor of the ovary: Case series and review of treatment strategies.
Yingao Zhang, S Allison Staley, Katherine Tucker, Leslie H Clark.
Gynecol Oncol Rep, 2019 Mar 01; 28. PMID: 30815527    Free PMC article.
Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective.
Richard Macaulay, Amit Ahuja, +2 authors, James W Shaw.
Clinicoecon Outcomes Res, 2019 Apr 03; 11. PMID: 30936729    Free PMC article.
Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study.
Anjie Zhu, Peng Yuan, +7 authors, Binghe Xu.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186682    Free PMC article.
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Kenichi Inoue, Masato Takahashi, +6 authors, Junji Tsurutani.
Invest New Drugs, 2020 Jan 18; 38(5). PMID: 31950374    Free PMC article.
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis.
Javier Cortes, Chris Twelves.
Breast J, 2019 Nov 30; 26(7). PMID: 31782589    Free PMC article.
A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK).
Min Ho Park, Soo Jung Lee, +14 authors, Joon Jeong.
Breast, 2020 Sep 28; 54. PMID: 32980648    Free PMC article.
Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications.
Noémie Legrand, Dan A Dixon, Cyril Sobolewski.
World J Gastroenterol, 2020 Oct 01; 26(35). PMID: 32994684    Free PMC article.
Tumor Lysis Syndrome After a Single Dose of Atezolizumab with Nab-Paclitaxel: A Case Report and Review of Literature.
Xavier Carrier, Sumit Gaur, Alexander Philipovskiy.
Am J Case Rep, 2020 Sep 17; 21. PMID: 32934194    Free PMC article.
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.
Hope S Rugo, Veronique Dieras, +14 authors, Sara M Tolaney.
Breast Cancer Res Treat, 2020 Aug 14; 184(1). PMID: 32789591    Free PMC article.
Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer.
Jinhong Shi, Feiqi Liu, Yanqiu Song.
Cancer Manag Res, 2020 Oct 17; 12. PMID: 33061626    Free PMC article.
Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.
Tsung-Ching Lai, Chih-Yeu Fang, +5 authors, Michael Hsiao.
Cell Commun Signal, 2020 Oct 23; 18(1). PMID: 33087151    Free PMC article.
Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians.
Fabio Marazzi, Armando Orlandi, +10 authors, Vincenzo Valentini.
Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846945    Free PMC article.
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.
Anne-Claire Hardy-Bessard, Fabien Brocard, +12 authors, George Emile.
Breast, 2020 Nov 15; 54. PMID: 33188992    Free PMC article.
Management of Brain and Leptomeningeal Metastases from Breast Cancer.
Alessia Pellerino, Valeria Internò, +3 authors, Roberta Rudà.
Int J Mol Sci, 2020 Nov 18; 21(22). PMID: 33198331    Free PMC article.
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Junji Tsurutani, Yukinori Sakata, Toshiyuki Matsuoka.
Breast Cancer, 2018 Oct 17; 26(2). PMID: 30324551    Free PMC article.
SEOM clinical guidelines in advanced and recurrent breast cancer (2018).
J I Chacón López-Muñiz, L de la Cruz Merino, +7 authors, S López-Tarruella Cobo.
Clin Transl Oncol, 2019 Jan 09; 21(1). PMID: 30617924    Free PMC article.
Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo.
Kenta Watanabe, Yoshihiro Yui, +4 authors, Tomoatsu Kimura.
Oncotarget, 2019 Feb 06; 10(2). PMID: 30719211    Free PMC article.
Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets.
Renato B Pereira, Nikolai M Evdokimov, +5 authors, Nelson G M Gomes.
Mar Drugs, 2019 Jun 05; 17(6). PMID: 31159480    Free PMC article.
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Lee Schwartzberg, Kristi McIntyre, +5 authors, Linda Vahdat.
BMC Cancer, 2019 Jun 15; 19(1). PMID: 31195996    Free PMC article.
PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.
Sandeep Rajput, Zhanfang Guo, Shunqiang Li, Cynthia X Ma.
Oncotarget, 2019 Jun 21; 10(38). PMID: 31217901    Free PMC article.
The Phylum Bryozoa as a Promising Source of Anticancer Drugs.
Blanca Figuerola, Conxita Avila.
Mar Drugs, 2019 Aug 21; 17(8). PMID: 31426556    Free PMC article.
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Wataru Goto, Shinichiro Kashiwagi, +10 authors, Masaichi Ohira.
BMC Cancer, 2020 Dec 12; 20(1). PMID: 33302911    Free PMC article.
Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer.
Vito Lorusso, Agnese Latorre, Francesco Giotta.
J Oncol, 2020 Dec 15; 2020. PMID: 33312203    Free PMC article.
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, +10 authors, Javier Cortés.
Contemp Clin Trials Commun, 2020 Dec 19; 20. PMID: 33336109    Free PMC article.
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Marilia Barreca, Virginia Spanò, +15 authors, Francesco Bertoni.
Mar Drugs, 2020 Dec 10; 18(12). PMID: 33291602    Free PMC article.
Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.
April L Risinger, Lin Du.
Nat Prod Rep, 2019 Nov 26; 37(5). PMID: 31764930    Free PMC article.
The complete mitochondrial genome of sponge Halichondria okadai (Demospongiae, Suberitida, Halichondriidae) from Korea water.
Hana Kim, Hyung June Kim, +4 authors, Dong Won Kang.
Mitochondrial DNA B Resour, 2017 Nov 27; 2(2). PMID: 33474017    Free PMC article.
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
B Pellegrino, L Cavanna, +19 authors, A Musolino.
ESMO Open, 2021 Jan 06; 6(1). PMID: 33399082    Free PMC article.
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
Otto Metzger Filho, Anita Giobbie-Hurder, +9 authors, Erica L Mayer.
Breast Cancer Res Treat, 2020 Oct 08; 185(1). PMID: 33025482
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Toshinari Yamashita, Hidetoshi Kawaguchi, +16 authors, Masakazu Toi.
Invest New Drugs, 2020 Aug 25; 39(1). PMID: 32833136    Free PMC article.
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
Luc Cabel, Matthieu Carton, +20 authors, Florence Lerebours.
Breast, 2021 Feb 10; 56. PMID: 33561617    Free PMC article.
Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells.
Yuki Matsunaga, Toshimitsu Yamaoka, +6 authors, Junji Tsurutani.
Antibodies (Basel), 2021 Feb 05; 10(1). PMID: 33535554    Free PMC article.
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
C De Angelis, D Bruzzese, +16 authors, G Arpino.
ESMO Open, 2021 Feb 19; 6(2). PMID: 33601296    Free PMC article.
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective.
Peng Yuan, Binghe Xu.
Breast Cancer (Dove Med Press), 2021 Mar 05; 13. PMID: 33658845    Free PMC article.
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer.
Albert Gris-Oliver, Yasir H Ibrahim, +21 authors, Violeta Serra.
Br J Cancer, 2021 Mar 17; 124(9). PMID: 33723394    Free PMC article.
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Yu-Ju Lin, Chun-Nan Kuo, Yu Ko.
Breast, 2021 Mar 12; 57. PMID: 33706025    Free PMC article.
Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305.
Iain R Macpherson, Yaohua He, Carlo Palmieri.
Breast Cancer Res, 2021 Mar 20; 23(1). PMID: 33736675    Free PMC article.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Norikazu Masuda, Hiroko Bando, +17 authors, Masakazu Toi.
Breast Cancer Res Treat, 2021 Mar 26; 188(1). PMID: 33763789    Free PMC article.
Overview of recent advances in metastatic triple negative breast cancer.
David O'Reilly, Maha Al Sendi, Catherine M Kelly.
World J Clin Oncol, 2021 Mar 27; 12(3). PMID: 33767972    Free PMC article.
Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer.
Pavani Chalasani, Kiah Farr, +6 authors, Hannah Linden.
Breast Cancer Res Treat, 2021 Apr 03; 188(1). PMID: 33797651    Free PMC article.
Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer.
Renaud Sabatier, Johan Martin, +8 authors, Anthony Goncalves.
J Clin Med, 2021 Apr 04; 10(6). PMID: 33803894    Free PMC article.
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial.
Luc Cabel, Frédérique Berger, +11 authors, Francois-Clement Bidard.
Br J Cancer, 2021 Jan 22; 124(7). PMID: 33473163    Free PMC article.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Eriseld Krasniqi, Laura Pizzuti, +30 authors, Patrizia Vici.
Int J Med Sci, 2021 Apr 17; 18(10). PMID: 33859534    Free PMC article.
Effect of renal function on neutrophil decreases following eribulin administration.
Norifumi Suzuki, Hiroyuki Tanaka, +4 authors, Masato Takahashi.
Cancer Rep (Hoboken), 2020 Oct 22; 3(5). PMID: 33085846    Free PMC article.
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
T Grinda, A Antoine, +24 authors, S Delaloge.
ESMO Open, 2021 Apr 26; 6(3). PMID: 33895695    Free PMC article.
Molecular Biology in the Breast Clinics-Current status and future perspectives.
Vani Parmar, Nita S Nair, Purvi Thakkar, Garvit Chitkara.
Indian J Surg Oncol, 2021 May 18; 12(Suppl 1). PMID: 33994723    Free PMC article.
Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States.
Sarah S Mougalian, Jonathan K Kish, +2 authors, Bruce A Feinberg.
Adv Ther, 2021 Jan 26; 38(5). PMID: 33491157    Free PMC article.
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Mario Hlevnjak, Markus Schulze, +28 authors, Andreas Schneeweiss.
JCO Precis Oncol, 2021 May 27; 5. PMID: 34036222    Free PMC article.
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Siao-Nge Hoon, Peter Kh Lau, +3 authors, Andrew D Redfern.
Cochrane Database Syst Rev, 2021 May 27; 5. PMID: 34037241    Free PMC article.
Systematic Review.
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive.
Dey Nandini, Aske Jennifer, De Pradip.
Pharmaceuticals (Basel), 2021 Jun 03; 14(5). PMID: 34065837    Free PMC article.
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models.
Keiji Furuuchi, Katherine Rybinski, +11 authors, Toshimitsu Uenaka.
Cancer Sci, 2021 Mar 24; 112(6). PMID: 33756060    Free PMC article.
TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.
María Paz Saldías, Diego Maureira, +6 authors, Oscar Cerda.
Front Oncol, 2021 Jun 29; 11. PMID: 34178620    Free PMC article.
Systematic Review.
Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
Qi Zhao, Rachel Hughes, +5 authors, Ananth Kadambi.
BMC Cancer, 2021 Jul 02; 21(1). PMID: 34193107    Free PMC article.
Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Masato Takahashi, Kenichi Inoue, +8 authors, Junji Tsurutani.
Breast Cancer, 2021 Mar 08; 28(4). PMID: 33677779    Free PMC article.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Kenjiro Aogi, Kenichi Watanabe, +13 authors, Shinji Ohno.
Int J Clin Oncol, 2021 Apr 24; 26(7). PMID: 33891194    Free PMC article.
Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients.
I E de Kruijff, A M Sieuwerts, +11 authors, S Sleijfer.
Front Oncol, 2021 Jul 13; 11. PMID: 34249756    Free PMC article.
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study.
Yannan Zhao, Ning Xie, +14 authors, Biyun Wang.
Ther Adv Med Oncol, 2021 Jul 23; 13. PMID: 34290830    Free PMC article.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Sara M Balch, Ines Vaz-Luis, +11 authors, Rachel A Freedman.
Breast Cancer Res Treat, 2021 Jul 25; 189(2). PMID: 34302589
Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.
Hye In Lim, Y U Sun, +2 authors, Robert M Hoffman.
In Vivo, 2021 Aug 20; 35(5). PMID: 34410939    Free PMC article.
A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17).
Ippei Fukada, Yoshinori Ito, +17 authors, Norikazu Masuda.
Breast Cancer Res Treat, 2021 Sep 24; 190(3). PMID: 34554370
Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient.
Marie Tsunogae, Satoru Fujiwara, +3 authors, Michi Kawamoto.
Intern Med, 2021 Mar 09; 60(16). PMID: 33678744    Free PMC article.
Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
Hisako Ono, Mano Horinaka, +5 authors, Toshiyuki Sakai.
Cancer Sci, 2021 Jul 22; 112(10). PMID: 34288272    Free PMC article.
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO Study.
Nicholas C Turner, Judith Balmaña, +27 authors, BRAVO Steering Committee and the BRAVO investigators.
Clin Cancer Res, 2021 Jul 25; 27(20). PMID: 34301749    Free PMC article.
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.
Shogo Nakamoto, Junichiro Watanabe, +2 authors, Masahiko Ikeda.
Sci Rep, 2021 Nov 04; 11(1). PMID: 34728668    Free PMC article.
Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm.
Timothee Olivier, Vinay Prasad.
Transl Oncol, 2021 Oct 24; 15(1). PMID: 34688044    Free PMC article.